

Additional file 4 *Plasmodium vivax* genotypes from two groups of patients treated with combined chloroquine and primaquine by the intermittent single dose (ISD) and 14-day (T14) regimens

RFLP genotype:	Treatment regimen (CQ-PQ):	
	ISD	14-day
<i>cspr-msp3α</i>		
vk247-A	15	18
vk247-B	4	4
vk247-C	0	3
Vk210-A	0	1
vk210-B	12	23
vk210-C	21	23
vk210-g	1	2
vk210-K	1	6
vk210-F	1	0
vk210-E	2	1
vk210-D	1	2
Mixed genotypes:	7*	3**
ND	2	0
Total	67	86

RFPL, restriction fragment length polymorphism; CQ, chloroquine; PQ, primaquine; * mixed genotype infections: five with *cspr* (vk210-247) and *msp3α* (A, n=3; B, n=1; C, n=1); two with vk247 and *msp3α* (AB and AC); ND, not determined (one sample did not amplify *msp3α* /and the other sample was not available for PCR analysis); ** All were mixed genotype infections, with *cspr* and *msp3α* –A; no differences in the proportions of genotypes between treatment groups were detected, with Fisher’s exact test ($\alpha=0.05$), $p=0.248$